---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-118092"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:21:51.243522+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech raises $10M via public offering of 5.9M units at $1.70/unit

## Summary
- Sold 5,885,000 units at $1.70/unit, each consisting of one share common stock and one warrant (exercise $1.70, 5-year term).
- Gross proceeds ~$10.0M; net proceeds for operations including R&D, clinical trials, manufacturing, working capital.
- Directors and officers purchased ~$2.9M of units in the offering.
- Warrants contain anti-dilution adjustment: if dilutive issuance below current exercise price, exercise price reduces to that lower price (one-time).
- Offering closed November 14, 2023; Roth Capital acted as exclusive placement agent.

## SEC filing metadata
- accession: 0001104659-23-118092
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000110465923118092/0001104659-23-118092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000110465923118092/tm2330640d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-118092
- JSON: https://secwatch.observer/filing/0001104659-23-118092.json
- Plain text: https://secwatch.observer/filing/0001104659-23-118092.txt

## Key facts
- Material Agreements
  Fortress Biotech, Inc. entered into Securities Purchase Agreement with the purchasers party thereto valued at approximately $10.0 million (effective 2023-11-10).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the purchasers party thereto
  - Value: approximately $10.0 million
  - Effective: 2023-11-10
  source text: a Securities Purchase Agreement (the “ Securities Purchase Agreement ”), dated November 10, 2023, between the Company and the purchasers party thereto.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000110465923118092/0001104659-23-118092-index.htm
- Material Agreements
  Fortress Biotech, Inc. entered into Placement Agent Agreement with Roth Capital Partners, LLC valued at 7.0% of the aggregate gross proceeds (effective 2023-11-10).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Roth Capital Partners, LLC
  - Value: 7.0% of the aggregate gross proceeds
  - Effective: 2023-11-10
  source text: a Placement Agent Agreement, dated as of November 10, 2023, between the Company and Roth (the “ Placement Agent Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000110465923118092/0001104659-23-118092-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.